Physician profile
Maya Gupta
NPI 1811011646
$2,293.42
in general payments reported to CMS, 2019-2025
24 companies · $580 in 2025
The $580 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2021: $290 · 2022: $85.48 · 2023: $473 · 2024: $732 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Products, Lp | $354.79 | 2021-2022 | |
| Gilead Sciences, INC. | $319.25 | 2024-2025 | Yeztugo |
| Viiv Healthcare Company | $309.04 | 2019-2025 | Rukobia, Dovato |
| Paratek Pharmaceuticals, INC. | $192.93 | 2022-2025 | Nuzyra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.83 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $150.02 | 2023-2025 | Rexulti, Nuedexta |
| Insmed, INC. | $148.72 | 2023-2025 | Arikayce |
| Neurocrine Biosciences, INC. | $128.49 | 2023-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $78.35 | 2023-2024 | Austedo Xr |
| Bausch Health US, LLC | $61.75 | 2023-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $53.13 | 2023-2024 | Spravato, Invega |
| Tris Pharma INC | $51.28 | 2023-2025 | Dyanavel Xr |
| Alkermes, INC. | $39.76 | 2024 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $34.28 | 2025 | Fanapt |
| Merck Sharp & Dohme LLC | $28.31 | 2024-2025 | Pifeltro, Delstrigo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $26.01 | 2024 | Cobenfy |
| Axsome Therapeutics, INC. | $24.97 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $24.39 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $23.62 | 2024 | |
| Almatica Pharma LLC | $23.09 | 2023 | Gralise |
| Allergan, INC. | $17.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.83 | 2025 | Trintellix |
| Noven Therapeutics, LLC | $15.91 | 2024 | Xelstrym |
| Abbvie INC. | $14.04 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.